These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37004925)

  • 1. Oxidation-labile linkers for controlled drug delivery.
    Carneiro A; Santana L; Matos MJ
    Bioorg Med Chem Lett; 2023 May; 87():129264. PubMed ID: 37004925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smart linkers in polymer-drug conjugates for tumor-targeted delivery.
    Chang M; Zhang F; Wei T; Zuo T; Guan Y; Lin G; Shao W
    J Drug Target; 2016; 24(6):475-91. PubMed ID: 26560242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide-drug conjugate-based novel molecular drug delivery system in cancer.
    Zhu YS; Tang K; Lv J
    Trends Pharmacol Sci; 2021 Oct; 42(10):857-869. PubMed ID: 34334251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
    Tsuchikama K
    Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxime-Linked Peptide-Daunomycin Conjugates as Good Tools for Selection of Suitable Homing Devices in Targeted Tumor Therapy: An Overview.
    Mező G; Gomena J; Ranđelović I; Dókus EL; Kiss K; Pethő L; Schuster S; Vári B; Vári-Mező D; Lajkó E; Polgár L; Kőhidai L; Tóvári J; Szabó I
    Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide-Drug Conjugates with Different Linkers for Cancer Therapy.
    Alas M; Saghaeidehkordi A; Kaur K
    J Med Chem; 2021 Jan; 64(1):216-232. PubMed ID: 33382619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment.
    Edupuganti VVSR; Tyndall JDATDA; Gamble AB
    Recent Pat Anticancer Drug Discov; 2021; 16(4):479-497. PubMed ID: 33966624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protease-activated prodrugs: strategies, challenges, and future directions.
    Poreba M
    FEBS J; 2020 May; 287(10):1936-1969. PubMed ID: 31991521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asymmetric peptide dendrimers are effective linkers for antibody-mediated delivery of diverse payloads to b cells in vitro and in vivo.
    Shah ND; Parekh HS; Steptoe RJ
    Pharm Res; 2014 Nov; 31(11):3150-60. PubMed ID: 24848340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening of chemical linkers for development of pullulan bioconjugates for intravitreal ocular applications.
    Balasso A; Subrizi A; Salmaso S; Mastrotto F; Garofalo M; Tang M; Chen M; Xu H; Urtti A; Caliceti P
    Eur J Pharm Sci; 2021 Jun; 161():105785. PubMed ID: 33667663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain penetrating peptides and peptide-drug conjugates to overcome the blood-brain barrier and target CNS diseases.
    Zhou X; Smith QR; Liu X
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Jul; 13(4):e1695. PubMed ID: 33470550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering peptide drug therapeutics through chemical conjugation and implication in clinics.
    Rizvi SFA; Zhang H; Fang Q
    Med Res Rev; 2024 Nov; 44(6):2420-2471. PubMed ID: 38704826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Advances and Trends in Chemical CPP-Drug Conjugation Techniques.
    Gayraud F; Klußmann M; Neundorf I
    Molecules; 2021 Mar; 26(6):. PubMed ID: 33805680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous stimuli-responsive linkers in nanoliposomal systems for cancer drug targeting.
    Faal Maleki M; Jafari A; Mirhadi E; Askarizadeh A; Golichenari B; Hadizadeh F; Jalilzadeh Moghimi SM; Aryan R; Mashreghi M; Jaafari MR
    Int J Pharm; 2019 Dec; 572():118716. PubMed ID: 31705978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gold nanoparticles stabilize peptide-drug-conjugates for sustained targeted drug delivery to cancer cells.
    Kalimuthu K; Lubin BC; Bazylevich A; Gellerman G; Shpilberg O; Luboshits G; Firer MA
    J Nanobiotechnology; 2018 Mar; 16(1):34. PubMed ID: 29602308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in Antibody-Drug Conjugate Design: Current Clinical Landscape and Future Innovations.
    Gauzy-Lazo L; Sassoon I; Brun MP
    SLAS Discov; 2020 Sep; 25(8):843-868. PubMed ID: 32192384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type of pH sensitive linker reveals different time-dependent intracellular localization, in vitro and in vivo efficiency in alpha-fetoprotein receptor targeted doxorubicin conjugate.
    Mollaev M; Gorokhovets N; Nikolskaya E; Faustova M; Zabolotsky A; Zhunina O; Sokol M; Zamulaeva I; Severin E; Yabbarov N
    Int J Pharm; 2019 Mar; 559():138-146. PubMed ID: 30599230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate.
    Sheyi R; de la Torre BG; Albericio F
    Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural optimization of a "smart" doxorubicin-polypeptide conjugate for thermally targeted delivery to solid tumors.
    Furgeson DY; Dreher MR; Chilkoti A
    J Control Release; 2006 Jan; 110(2):362-369. PubMed ID: 16303202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrin-Targeted Peptide- and Peptidomimetic-Drug Conjugates for the Treatment of Tumors.
    Arosio D; Manzoni L; Corno C; Perego P
    Recent Pat Anticancer Drug Discov; 2017; 12(2):148-168. PubMed ID: 28164756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.